Demonstrates individualized survival estimates in stage IB lung squamous cell carcinoma, suggesting tailored treatment approaches.
This study gives individualized survival estimates for stage IB LSCC, backing a risk-adapted conservative adjuvant treatment approach. High-risk subgroups got no extra benefit from postoperative chemotherapy, which may help integrate precision medicine and shared decision-making in early-stage LSCC management.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: